Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug: givosiran, givosiran sodium | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 247 | 0.85 |
| pathways Reactome | 4 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 10171
Sealed predictions
- ALAS1 in dopamine neurons, braak-0.38 (p 0.311) → +0.19 (p 0.630)receipt 10178
Swarm cases
receipt 10178: ALAS1 in dopamine neurons, braak
- power
- full sample -0.16 (p 0.515, n 18), 95% CI -0.59 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.658, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.23 (p 0.351, n 18). could be the mix.
- skeptic
- leave-one-out range -0.24 to -0.05, sign flips 0; without severely affected donors -0.16 (p 0.515, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ALAS1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts